Rallybio (RLYB) Fundamental Analysis: Revenue, Earnings & Valuation

0.40 / 10

Underperform

Fundamental analysis rates RLYB as Underperform with a 0.4/10 health score. Asset‑MV and Profit‑MV show modest strength, but PB‑ROE is negative and inventory turnover days are high, indicating valuation pressure and operational inefficiency. Overall fundamentals are weak and warrant caution.

Analysis Checks(6/10)

Profit-MV

Value0.68

Score2/3

Weight-1.53%

1M Return0.17%

Net income-Revenue

Value-0.04

Score2/3

Weight1.97%

1M Return-0.22%

PB-ROE

Value-0.60

Score0/3

Weight43.33%

1M Return-6.09%

Current assets turnover ratio

Value0.01

Score0/3

Weight38.15%

1M Return-6.07%

Cash-UP

Value-0.16

Score3/3

Weight-27.75%

1M Return2.87%

Total assets turnover ratio

Value0.01

Score0/3

Weight40.40%

1M Return-6.03%

Cost of sales ratio (%)

Value57.03

Score3/3

Weight-16.91%

1M Return1.95%

Asset-MV

Value-0.55

Score2/3

Weight7.35%

1M Return-0.95%

Inventory turnover days

Value210.83

Score1/3

Weight21.59%

1M Return-2.65%

Cash-MV

Value0.03

Score2/3

Weight-6.61%

1M Return0.79%

Is RLYB undervalued or overvalued?

RLYB scores 0.40/10 on fundamentals and holds a Premium valuation at present. Backed by its -15.01% ROE, -1046.39% net margin, -4.84 P/E ratio, 0.75 P/B ratio, and 85.01% earnings growth, these metrics solidify its Underperform investment rating.